Nevro (NYSE: NVRO) is a public multinational medical technology company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has impacted the lives of over 28,000 patients around the world.
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States.
Support achievement of sales revenue targets and help grow market share for a specified territory by promoting, selling and servicing NEVRO products. Practice good territory management in terms of organization, administration and expense planning and control and train appropriate medical staff on products and procedures. This is a clinical sale with strong value added focus and an emphasis on improving patient care outcomes.